Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats
Reproductive Sciences · 2024
DOI: 10.1007/s43032-024-01496-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Sciences, 2024. Verfasst von Ayse Bozkurt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmacology, Van Yuzuncu Yil University, Van, Turkey. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Reperfusion Injury, Rolipram, Ovary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TUSEB, Ataturk University.
Abstract (Originalsprache)
This study aimed to examine the effect of Phosphodiesterase 4 (PDE4) inhibition on Aquaporin-5 (AQP5) and its potential cell signaling pathway in the ovarian ischemia reperfusion (OIR) model. Thirty adult female rats were divided into five groups: Group 1; Control: Sham operation, Group 2; OIR that 3 hour ischemia followed by 3 hour reperfusion, Group 3; OIR + Rolipram 1 mg/kg, Group 4; OIR + Rolipram 3 mg/kg, Group 5; OIR + Rolipram 5 mg/kg. Rolipram was administered intraperitoneally to the rats in groups 3-4 and 5 at determined doses 30 minutes before reperfusion. From ovary tissue; Tumor necrosis factor-a (TNF-α), Cyclic adenosine monophosphate (cAMP), Nuclear factor kappa (NF-κB), Interleukin-6 (IL-6), Phosphodiesterase 4D (PDE4D), Mitogen-activated protein kinase (MAPK) and AQP5 levels were measured by ELISA. We also measured the level of AQP5 in ovary tissue by real-time reverse-transcription polymerase chain reaction (RT-PCR). In the OIR groups; TNF-α, NF-κB, IL-6, MAPK inflammatory levels increased, and cAMP and AQP5 levels decreased, which improved with the administration of rolipram doses. Also histopathological results showed damaged ovarian tissue after OIR, while rolipram administration decrased tissue damage in a dose dependent manner. We propose that the protective effect of PDE4 inhibition in OIR may be regulated by AQP5 and its potential cell signaling pathway and may be a new target in OIR therapy. However, clinical studies are needed to appraise these data in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmacology, Van Yuzuncu Yil University, Van, Turkey.
- Faculty of Pharmacy, Department of Pharmacology, Erzincan Binali Yildirim University, Erzincan, Turkey.
- Faculty of Medicine, Department of Pharmacology, Ataturk University, Erzurum, 25240, Turkey.
- Department of Anesthesiology and Reanimation, Educational and Research Hospital, Erzurum, Turkey.
- Faculty of Medicine, Department of Histology and Embryology, Kafkas University, Kars, Turkey.
- Clinical Research, Development and Design Application and Research Center, Ataturk University, 25240, Erzurum, Turkey.
ORCID-Profile: Ayse Bozkurt, Zeynep Karakoy, Pelin Aydin, Bengul Ozdemir, Erdem Toktay, Zekai Halici, Elif Cadirci
Förderung
- TUSEB
- Ataturk University
Zitieren
APA
Bozkurt, A., Karakoy, Z., Aydin, P., Ozdemir, B., Toktay, E., Halici, Z., & Cadirci, E. (2024). Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats. Reproductive Sciences. https://doi.org/10.1007/s43032-024-01496-w
Vancouver
Bozkurt A, Karakoy Z, Aydin P, Ozdemir B, Toktay E, Halici Z, et al. Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats. Reproductive Sciences. 2024. doi:10.1007/s43032-024-01496-w
BibTeX
@article{Bozkurt2024,
author = {Bozkurt, Ayse and Karakoy, Zeynep and Aydin, Pelin and Ozdemir, Bengul and Toktay, Erdem and Halici, Zekai and Cadirci, Elif},
title = {Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats},
journal = {Reproductive Sciences},
year = {2024},
doi = {10.1007/s43032-024-01496-w}
}
EUVIMED